Clinical Trial Detail

NCT ID NCT03088878
Title A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of California, San Diego
Indications

mantle cell lymphoma

CLL/SLL

Therapies

Cirmtuzumab

Cirmtuzumab + Ibrutinib

Ibrutinib

Age Groups: adult senior

No variant requirements are available.